The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Pfizer (Inst)
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
 
Audreylie Lemelin
No Relationships to Disclose
 
Matthew Scott Ernst
No Relationships to Disclose
 
Connor Wells
No Relationships to Disclose
 
Vishal Navani
Speakers' Bureau - Ekas; Ipsos; Kyowa Kirin
 
Bradley Alexander McGregor
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Merck; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Pfizer/EMD Serono (Inst); Seattle Genetics/Astellas (Inst)
 
Shirley S. Wong
No Relationships to Disclose
 
Sumanta Monty Pal
Research Funding - Allogene Therapeutics (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - crispr therapeutics; Roche
 
Naveen S. Basappa
Stock and Other Ownership Interests - illumiSonics
Honoraria - Astellas Pharma; Eisai; Ipsen; Janssen; Merck; Pfizer
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; EMD Serono; Ipsen; Janssen; Merck; Pfizer; Roche Canada
Travel, Accommodations, Expenses - Eisai; Janssen
 
Anil Kapoor
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst)
 
Jae-Lyun Lee
Stock and Other Ownership Interests - Amgen; BeiGene; Black Diamond Therapeutics; Innovent Biologics; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Myovant Sciences; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - AstraZeneca; Merck; Oscotec; Sanofi
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); GI Innovation (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Frede Donskov
No Relationships to Disclose
 
Haoran Li
No Relationships to Disclose
 
Takeshi Yuasa
Honoraria - Bristol-Myers Squibb; Novartis; Ono Pharmaceutical
 
Rose Chang
Research Funding - Pfizer (Inst)
 
Lynn Huynh
Research Funding - Epizyme; Novartis; Pfizer; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Novartis
 
Catherine Nguyen
Research Funding - Pfizer (Inst)
 
Ashley Holub
Employment - Artech Providing Services for J&J; GlaxoSmithKline
Honoraria - Philips Healthcare
Research Funding - Pfizer (Inst)
 
Louise Clear
Stock and Other Ownership Interests - SQZ Biotech
Research Funding - Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Inventor on patent application: FORMULATIONS OF ACTIVATING ANTIGEN CARRIERS (PCT/US2021/073142)
 
Mei Sheng Duh
No Relationships to Disclose
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)